SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 17, 2020
Leap Therapeutics, Inc.
(Exact name of registrant as specified in
|(State or other jurisdiction
|(IRS Employer |
Street, Suite B1-1
|(Address of principal executive offices)
Registrant’s telephone number, including
area code: (617) 714-0360
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
|¨||Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
|¨||Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)).
|¨||Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class
||Name of each exchange on which |
|Common Stock, par value $0.001
||Nasdaq Global Market|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter)
growth company x
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.02. Termination of
a Material Definitive Agreement.
As previously disclosed, on September 7,
2018, Leap Therapeutics, Inc. (the “Company”) entered into a Distribution Agreement (the “Distribution Agreement”)
with Raymond James & Associates, Inc. (“Raymond James”) to offer and sell, at the Company’s option, shares
of common stock, par value $0.001 per share (the “Common Stock”), having aggregate gross sales proceeds of up to $30
million, from time to time, through an “at the market” equity offering program under which Raymond James acted as agent.
On June 17, 2020, the Company delivered
written notice to Raymond James, effective as of such date, to terminate the Distribution Agreement pursuant to Section 8(a) thereof.
During the term of the Distribution Agreement, the Company sold an aggregate of 1,033,147 shares of Common Stock pursuant to the
Distribution Agreement, resulting in net proceeds of approximately $1,922,842.
A copy of the Distribution Agreement was
filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September
7, 2018. The description of the Distribution Agreement contained in such Current Report on Form 8-K does not purport to be complete
and is qualified in its entirety by reference to the copy of the Distribution Agreement filed as Exhibit 1.1 to the Form 8-K dated
September 7, 2018.
Item 8.01. Other Events.
On June 17, 2020, the Company issued a press
release announcing a proposed underwritten public offering of its Common Stock and pre-funded warrants to purchase shares of Common
Stock. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein
Item 9.01. Financial
Statements and Exhibits.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
||LEAP THERAPEUTICS, INC.|
|Dated: June 17, 2020
||/s/ Douglas E. Onsi|
||Douglas E. Onsi|
||Chief Executive Officer and President|